74 / 74 · 3:02 · Original AXON film
FOXO4-DRI and Cancer
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
What does the research show?
FOXO4-DRI is an experimental peptide being studied for its ability to eliminate some senescent cells. These are cells that have stopped dividing but remain biologically active. The cancer research is interesting, but the evidence needs careful interpretation. [1]
2017: senescent-cell research
The original 2017 Cell study investigated the interaction between FOXO4 and p53, proteins involved in cellular stress responses. In laboratory experiments, FOXO4-DRI promoted the death of certain senescent cells. Mouse experiments also reported improvements in selected measures of chemotherapy-related damage and age-related decline. This was preclinical research, not proof of cancer treatment in people. [1]
2021: the tumor surroundings
In 2021, researchers publishing in JCI Insight studied non-small cell lung cancer models. They found that radiation-induced, senescence-like fibroblasts surrounding tumors could help nearby cancer cells resist radiation. [2]
Mouse findings have limits
In the relevant mouse comparisons, adding FOXO4-DRI to radiation reduced tumor volume and weight compared with radiation in the presence of those senescence-like fibroblasts. The proposed benefit involved changing the tumor's surroundings. The study did not establish that FOXO4-DRI alone reliably shrinks established tumors, or that it prevents cancer recurrence in patients. [2]
2025: binding is not clinical benefit
A 2025 Nature Communications study added molecular detail. It mapped how FOXO4-DRI binds to a region of p53 called the transactivation domain, particularly TAD2. Understanding that interaction can guide drug development. A molecular binding result does not establish clinical effectiveness or safety. [3]
CL04183 is a different candidate
Cleara Biotech is developing a distinct, optimized candidate called CL04183 for cancers involving impaired p53 signaling. Company researchers described a planned phase-one study in a 2026 conference abstract. Results or development plans for CL04183 should not be presented as evidence for the original FOXO4-DRI peptide. [4] [5]
Human evidence: the boundary
Our November 5, 2026 searches of ClinicalTrials.gov found no matching registered studies under FOXO4-DRI or the related candidate names checked. The studies discussed here do not establish a safe human dose or demonstrate cancer-treatment benefit in people. [6] [1] [2] [3]
Research, not established care
Senescence is context-dependent, and removing these cells is not automatically beneficial in every tissue or cancer. FOXO4-DRI remains a research subject, not a substitute for established cancer care. Anyone considering experimental cancer treatment should discuss legitimate clinical-trial options with their oncology team. [1] [2] [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Baar et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. →Primary cell and mouse study
- Meng et al. (2021). Targeting senescence-like fibroblasts radiosensitizes non–small cell lung cancer and reduces radiation-induced pulmonary fibrosis. →Primary preclinical cancer study
- Bourgeois et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. →Primary structural and biophysical study
- Cleara Biotech. Company-reported CL04183 / CL04177 development. →Company development statement
- Sarlis et al. WIN 2026, abstract 40. Understanding and targeting p53 impairment in advanced cancer - Transitioning into the clinic. Printed p.152 (PDF p.155). →Company-authored conference abstract
- ClinicalTrials.gov. Named-term registry searches, November 5, 2026. →Dated registry search; not proof of universal absence
